Browse

The Efficacy and Safety of Testosterone Undecanoate (Nebido (R)) in Testosterone Deficiency Syndrome in Korean: A Multicenter Prospective Study

DC Field Value Language
dc.contributor.authorMoon, Du Geon-
dc.contributor.authorPark, Min Gu-
dc.contributor.authorLee, Sung Won-
dc.contributor.authorPark, Kwangsung-
dc.contributor.authorKim, Sae Woong-
dc.contributor.authorAhn, Tai Young-
dc.contributor.authorSeo, Ju Tae-
dc.contributor.authorLee, June Young-
dc.contributor.authorKim, Je Jong-
dc.contributor.authorYang, Dae Yul-
dc.contributor.authorPaick, Jae Seung-
dc.contributor.authorPark, Nam Cheol-
dc.contributor.authorPark, Jong Kwan-
dc.date.accessioned2012-06-28T07:07:36Z-
dc.date.available2012-06-28T07:07:36Z-
dc.date.issued2010-06-
dc.identifier.citationJOURNAL OF SEXUAL MEDICINE; Vol.7 6; 2253-2260ko_KR
dc.identifier.issn1743-6095-
dc.identifier.urihttps://hdl.handle.net/10371/77797-
dc.description.abstractIntroduction. Long-acting injectable testosterone undecanoate (TU, Nebido (R)), a new parenteral testosterone preparation, has recently been introduced to avoid frequent injections of the conventional injectable esters. Aims. To assess the efficacy and safety of long-acting injectable testosterone undecanoate (TU, Nebido (R)) in Korean patients with testosterone deficiency syndrome (TDS). Methods. One hundred thirty-three patients who complain of erectile dysfunction with serum testosterone level less than 3.5 ng/mL were injected with 1,000 mg of TU (4 mL/ample) on day 1, followed by another injection after 6 weeks and 18 weeks. For the safety profiles, serum hemoglobin (Hb), hematocrit (Hct), glucose, lipid profile, and prostate-specific antigen (PSA) were measured. Main Outcome Measures. Body mass index (BMI) was measured at the time of the first visit and after 12, 24 weeks. Primary efficacy was evaluated according to changes in the International Index of Erectile Function (IIEF) from the initial visit to the final visit (24 weeks) and from the initial visit to each visit. Secondary efficacy was assessed with changes of the Aging Males` Symptoms (AMS) Scale and the Global Efficacy Question (GEQ) for improvement of erectile function. Results. Mean age of patients was 54 +/- 9.6 years. Compared with pretreatment, no significant improvement in BMI was observed. Serum total testosterone and free testosterone were significantly increased at 12 weeks and were maintained until 24 weeks (P < 0.001). TU significantly decreased cholesterol (P < 0.0001). TU significantly improved total IIEF, all five domain scores of IIEF (P < 0.0001) and total AMS, all three domain scores of AMS (P < 0.0001). On GEQ, TU improved erectile function in 76.9% of subjects. On safety profile, TU significantly elevated Hb, Hct, and PSA at 24 weeks but within normal range. No serious adverse reactions were observed. Drop-out rate was 15.0%. Conclusions. In this prospective multicenter study, TU was effective, safe, and tolerable until 24 weeks in Korean TDS patients. Further well-controlled, long-term study should follow. Moon DG, Park MG, Lee SW, Park K, Park JK, Kim SW, Park NC, Ahn TY, Paick JS, Seo JT, Yang DY, Lee JY, and Kim JJ. The efficacy and safety of testosterone undecanoate (Nebido (R)) in testosterone deficiency syndrome in Korean: A multicenter prospective study. J Sex Med 2010;7:2253-2260.ko_KR
dc.language.isoenko_KR
dc.publisherWILEY-BLACKWELLko_KR
dc.subjectTestosterone Deficiency Syndromeko_KR
dc.subjectHypogonadismko_KR
dc.subjectKoreako_KR
dc.subjectTestosterone Undecanoateko_KR
dc.titleThe Efficacy and Safety of Testosterone Undecanoate (Nebido (R)) in Testosterone Deficiency Syndrome in Korean: A Multicenter Prospective Studyko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor문두건-
dc.contributor.AlternativeAuthor박민구-
dc.contributor.AlternativeAuthor이성원-
dc.contributor.AlternativeAuthor박광성-
dc.contributor.AlternativeAuthor박종관-
dc.contributor.AlternativeAuthor김새웅-
dc.contributor.AlternativeAuthor박남철-
dc.contributor.AlternativeAuthor안태영-
dc.contributor.AlternativeAuthor백재승-
dc.contributor.AlternativeAuthor서주태-
dc.contributor.AlternativeAuthor양대열-
dc.contributor.AlternativeAuthor이준영-
dc.contributor.AlternativeAuthor김재종-
dc.identifier.doi10.1111/j.1743-6109.2010.01765.x-
dc.citation.journaltitleJOURNAL OF SEXUAL MEDICINE-
dc.description.citedreferenceWang C, 2009, INT J IMPOT RES, V21, P1, DOI 10.1038/ijir.2008.41-
dc.description.citedreferenceLOTTI F, 2009, J SEX MED 1113-
dc.description.citedreferenceMorgentaler A, 2008, J UROLOGY, V180, P2307, DOI 10.1016/j.juro.2008.08.126-
dc.description.citedreferenceSaad F, 2007, ASIAN J ANDROL, V9, P291, DOI 10.1111/j.1745-7262.2007.00275.x-
dc.description.citedreferenceYassin AA, 2007, J SEX MED, V4, P497, DOI 10.1111/j.1743-6109.2007.00442.x-
dc.description.citedreferenceSeftel A, 2007, INT J IMPOT RES, V19, P2, DOI 10.1038/sj.ijir.3901366-
dc.description.citedreferenceYassin AA, 2007, CLIN INTERV AGING, V2, P577-
dc.description.citedreferenceYassin AA, 2006, WORLD J UROL, V24, P639, DOI 10.1007/s00345-006-0120-0-
dc.description.citedreferenceMorales A, 2006, AGING MALE, V9, P221, DOI 10.1080/13685530601063689-
dc.description.citedreferenceGreco EA, 2006, EUR UROL, V50, P940, DOI 10.1016/j.eururo.2006.06.049-
dc.description.citedreferenceNieschlag E, 2006, CLIN ENDOCRINOL, V65, P275, DOI 10.1111/j.1365-2265.2006.02618.x-
dc.description.citedreferenceMorales A, 2006, EUR UROL, V50, P407, DOI 10.1016/j.eururo.2006.07.001-
dc.description.citedreferenceYassin AA, 2006, J SEX MED, V3, P727, DOI 10.1111/j.1743-6109.2006.00267.x-
dc.description.citedreferenceTravison TG, 2006, J CLIN ENDOCR METAB, V91, P2509, DOI 10.1210/jc.2005-2508-
dc.description.citedreferenceBhasin S, 2006, J CLIN ENDOCR METAB, V91, P1995, DOI 10.1210/jc.2025-2847-
dc.description.citedreferenceGooren LJG, 2006, ASIAN J ANDROL, V8, P3, DOI 10.1111/j.1745-7262.2006.00105.x-
dc.description.citedreferenceIsidori AM, 2005, CLIN ENDOCRINOL, V63, P381, DOI 10.1111/j.1365-2265.2005.02350.x-
dc.description.citedreferenceSchubert M, 2004, J CLIN ENDOCR METAB, V89, P5429, DOI 10.1210/jc.2004-0897-
dc.description.citedreferenceO`Connor DB, 2004, J CLIN ENDOCR METAB, V89, P2837, DOI 10.1210/jc.2003-031354-
dc.description.citedreferenceDAIG I, 2003, HEALTH QUAL LIFE OUT, V1, P77-
dc.description.citedreferenceVon Eckardstein S, 2002, J ANDROL, V23, P419-
dc.description.citedreferenceNieschlag E, 1999, CLIN ENDOCRINOL, V51, P757-
dc.description.citedreferenceBehre HM, 1999, EUR J ENDOCRINOL, V140, P414-
dc.description.citedreferenceCHUNG TG, 1999, KOREAN J UROL, V40, P1334-
dc.description.citedreferenceZhang GY, 1998, J ANDROL, V19, P761-
dc.description.citedreferencePARTSCH CJ, 1995, EUR J ENDOCRINOL, V132, P514-
dc.description.citedreferenceWANG LZ, 1991, NEW DRUGS MARKET, V8, P28-
dc.description.citedreferenceOCARROLL R, 1984, BRIT J PSYCHIAT, V145, P146-
dc.description.tc3-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Urology (비뇨기과학전공)Journal Papers (저널논문_비뇨기과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse